MedPath

CalciMedica Secures $32.5M Credit Facility to Advance CRAC Channel Inhibitor Development

• CalciMedica has secured a $32.5M credit facility from Avenue Venture Opportunities Fund, with an initial $10M tranche extending cash runway into mid-2026.

• The company is advancing development of Auxora, their lead CRAC channel inhibitor, with Phase 2 trial data in acute kidney injury expected in 2025.

• The financing provides strategic flexibility for CalciMedica's clinical programs, including preparations for Phase 3 trials in acute pancreatitis.

CalciMedica Inc. (Nasdaq: CALC) has secured a credit facility of up to $32.5 million from Avenue Venture Opportunities Fund II, L.P., strengthening its financial position to advance novel calcium release-activated calcium (CRAC) channel inhibition therapies. The agreement includes an immediate $10 million funding tranche, extending the company's operational runway into mid-2026.

Strategic Financial Terms

The 3.5-year credit agreement provides significant flexibility with no minimum cash requirements or financial covenants. Beyond the initial $10 million, CalciMedica can access additional tranches totaling $22.5 million upon achieving specific milestones.

Advancing Clinical Development Programs

The funding comes at a crucial time as CalciMedica prepares for several significant clinical milestones. The company's lead candidate, Auxora, is currently being evaluated in multiple clinical trials targeting inflammatory and immunologic conditions.
"This credit agreement provides CalciMedica with additional flexibility as we prepare for multiple critical milestones throughout 2025," said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. "The facility extends our cash runway to the middle of 2026, providing us ample runway beyond the KOURAGE readout based on our current enrollment projections."

Key Clinical Programs and Timelines

The company is conducting several clinical trials evaluating Auxora across different indications:
  • KOURAGE trial: A Phase 2 study in patients with acute kidney injury and acute hypoxemic respiratory failure, with data expected in 2025
  • CRSPA trial: An ongoing Phase 1/2 study in pediatric patients with asparaginase-induced pancreatic toxicity
  • Preparations for Phase 3 program discussions with FDA regarding acute pancreatitis indication

Therapeutic Approach and Market Potential

CalciMedica's proprietary CRAC channel inhibition technology represents a novel approach to treating inflammatory and immunologic diseases. The company's focus on modulating immune response and protecting against tissue cell injury addresses conditions with significant unmet medical needs.
Chad Norman, Senior Portfolio Manager of Avenue Venture Opportunities Fund, expressed confidence in the investment: "We appreciate the potential of its lead pipeline candidate, Auxora, to treat acute inflammatory and immunologic diseases and look forward to its continued progress in clinical trials."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Highlighted Clinical Trials

A Study of Auxora in Patients With Severe COVID-19 Pneumonia

NCT04345614CompletedPhase 2
CalciMedica, Inc.
Posted 4/8/2020

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

NCT04195347RecruitingPhase 1
St. Jude Children's Research Hospital
Posted 9/4/2020

Related Topics

Auxora Shows 63% Mortality Reduction in COVID-19 Patients with Acute Kidney Injury

Post-hoc analysis of CARDEA Phase 2 trial reveals Auxora reduced mortality by 62.7% in COVID-19 patients with acute kidney injury compared to placebo, with benefits persisting through 60 days.
CalciMedica's CRAC channel inhibitor demonstrates promising tissue-protective and immunomodulatory effects in preclinical studies, suggesting potential therapeutic mechanism for AKI treatment.

Nuvation Bio Secures $250M Financing Package to Launch Novel Lung Cancer Drug Taletrectinib

Nuvation Bio has secured a $250 million non-dilutive financing deal with Sagard Healthcare Partners, including $150 million in royalty financing and up to $100 million in term loans.
The financing package is contingent on FDA approval of taletrectinib, a targeted therapy for ROS1-positive non-small cell lung cancer, expected in mid-2025.

Aligos Therapeutics Secures $105M Financing to Advance Hepatitis B Drug Development

Aligos Therapeutics has secured a $105 million private placement financing led by a life sciences investment firm, strengthening its position to advance ALG-000184 into Phase 2 clinical trials for chronic hepatitis B.
The financing structure includes a combination of common stock shares and warrants, with the transaction expected to close by February 13, 2025.

CARGO Therapeutics Advances Cell Therapy Pipeline with Firi-cel, CRG-023, and Novel Allogeneic Platform

CARGO Therapeutics anticipates interim analysis results from the Phase 2 FIRCE-1 study of firicabtagene autoleucel (firi-cel) in relapsed/refractory large B-cell lymphoma in 1H 2025.
The FDA has cleared the IND application for CRG-023, a tri-specific CAR T-cell therapy, with Phase 1 study enrollment expected to begin mid-2025 for B-cell malignancies.

Arch Biopartners Establishes Australian Subsidiary for Metablok Phase I Trial in Acute Kidney Injury

Arch Biopartners has created Arch Clinical Pty Ltd in Australia to facilitate a Phase I safety trial for Metablok, a drug candidate targeting acute kidney injury.
The Phase I trial application has been submitted to the Alfred Health Human Research Ethics Committee, with a decision anticipated in early 2019.

Assembly Biosciences Secures $30.1 Million Investment from Gilead to Boost Clinical Development

Assembly Biosciences has announced a significant $30.1 million investment from Gilead Sciences, comprising a $20.1 million equity investment and $10 million in accelerated funding. This investment aims to advance Assembly Bio's clinical development programs, particularly focusing on novel antiviral therapies for serious viral diseases. The funding will support the progression of Assembly Bio's clinical pipeline, including the acceleration of clinical development for ABI-6250, a candidate for hepatitis D virus treatment. With this investment, Gilead's ownership stake in Assembly Bio increases to 29.9%, and Assembly Bio's cash runway is extended to mid-2026.

Allarity Therapeutics' Stenoparib Shows Promise in Advanced Ovarian Cancer Phase 2 Trial

Allarity Therapeutics reports that two patients with advanced ovarian cancer have remained on stenoparib treatment for over 14 months in a Phase 2 trial.
The company's strong financial position, with $18.5 million in cash, supports the advancement of stenoparib towards potential FDA registration.

DiaMedica Announces ReMEDy2 Trial Updates and Q3 2024 Financial Results

DiaMedica Therapeutics modified its ReMEDy2 trial for acute ischemic stroke, including thrombolytic non-responders and increasing interim analysis sample size to 200 subjects.
Top-line interim results for the ReMEDy2 trial are now expected in Q4 2025, a shift from the previously projected Summer 2025 timeline.

Ocugen Secures $30 Million Debt Financing to Advance Gene Therapy Programs

Ocugen has secured a $30 million credit facility with Avenue Venture Opportunities Fund to support its clinical development programs and general corporate purposes.
The financing will primarily support the advancement of Ocugen's modifier gene therapies and the completion of the OCU400 Phase 3 clinical trial.

UroGen Pharma Secures $25M Loan as UGN-102 Awaits Potential FDA Approval

UroGen Pharma obtained a $25 million loan to support its corporate and working capital needs, with the loan's terms tied to FDA approval of UGN-102.
The loan's interest rate is based on the three-month Secured Overnight Financing Rate (SOFR) plus 7.25%, with potential for term extension upon FDA approval.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy